Voyager Therapeutics (VYGR) Other Non-Current Liabilities (2014 - 2024)

Voyager Therapeutics (VYGR) has 11 years of Other Non-Current Liabilities data on file, last reported at $39.4 million in Q3 2024.

• For the quarter ending Q3 2024, Other Non-Current Liabilities rose 108.09% year-over-year to $39.4 million; the trailing twelve-month figure through Sep 2024 stood at $39.4 million (up 108.09% YoY), and the FY2023 full-year result was $18.1 million, down 15.03% from the prior year.
• Other Non-Current Liabilities declined to $39.4 million in Q3 2024, from $41.2 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $44.4 million in Q4 2020 to a low of $18.1 million in Q4 2023.
• A 5-year average of $31.9 million and a median of $31.1 million in 2020 frame the typical range for Other Non-Current Liabilities.
• Across the five-year window, Other Non-Current Liabilities sank 46.3% in 2022 and surged 109.51% in 2024, its largest moves.
• Tracing VYGR's Other Non-Current Liabilities over 5 years: stood at $44.4 million in 2020, then retreated by 10.81% to $39.6 million in 2021, then sank by 46.24% to $21.3 million in 2022, then decreased by 15.03% to $18.1 million in 2023, then jumped by 117.57% to $39.4 million in 2024.
• Business Quant data shows VYGR's Other Non-Current Liabilities at $39.4 million in Q3 2024, $41.2 million in Q2 2024, and $43.0 million in Q1 2024.